Postoperative Outcomes in Patients With Hepato-biliary-pancreatic Cancer According to inBody Test
February 16, 2022 updated by: Takehiro Okabayashi, Kochi University
postoperative outcomes were evaluated by using inBody test
Study Overview
Detailed Description
postoperative outcomes were evaluated by using inBody test
Study Type
Observational
Enrollment (Anticipated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kochi, Japan, 781-8555
- Recruiting
- Takehiro Okabayashi
-
Contact:
- Takehiro Okabayashi
- Phone Number: +81- 88-837-3000
- Email: tokabaya@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
surgically treated patients who were suffering from hepato-biliary-pancreatic cancer
Description
Inclusion Criteria:
- surgically treated patients
Exclusion Criteria:
- a body weight loss of >10% during the 6 months before surgery; the presence of distant metastases; or seriously impaired function of vital organs because of respiratory, renal, or heart disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
long-term outcomes
Time Frame: 5year
|
overall survival rate
|
5year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
short-term outcomes
Time Frame: up to 24 weeks
|
postoperative complications
|
up to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2019
Primary Completion (Anticipated)
January 31, 2025
Study Completion (Anticipated)
January 31, 2030
Study Registration Dates
First Submitted
February 1, 2022
First Submitted That Met QC Criteria
February 16, 2022
First Posted (Actual)
February 25, 2022
Study Record Updates
Last Update Posted (Actual)
February 25, 2022
Last Update Submitted That Met QC Criteria
February 16, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- Point study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.